Pfizer (PFE) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7170811035

Vaccines, Medicines, Biosimilars, Injectables, Antivirals, Immunotherapies

Pfizer Inc. is a leading biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells a wide range of medicines and vaccines globally. With a rich history dating back to 1849, the company has established itself as a pioneer in the healthcare industry.

The company's diverse portfolio of products includes medicines and vaccines that cater to various therapeutic areas, such as cardiovascular metabolic, migraine, and women's health. Its popular brands include Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family, which are designed to improve the lives of patients worldwide.

In addition, Pfizer is at the forefront of infectious disease prevention and treatment, with a focus on addressing unmet medical needs. Its brands, such as Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba, have made significant contributions to the fight against infectious diseases. The company has also been instrumental in the development of COVID-19 prevention and treatment products, including Comirnaty and Paxlovid.

Pfizer's portfolio also includes biosimilars for chronic immune and inflammatory diseases, such as Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo. The company's products also cater to patients with amyloidosis, hemophilia, endocrine diseases, and sickle cell disease, with brands like Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin.

The company's sterile injectable and anti-infective medicines, including Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga, are designed to combat various infections and diseases. Furthermore, Pfizer's biologics, small molecules, immunotherapies, and biosimilars, such as Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi, are used to treat various types of cancer and other diseases.

In addition to its product portfolio, Pfizer is also involved in contract manufacturing, providing services to various clients in the healthcare industry. The company's products are distributed to a wide range of customers, including wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems.

Pfizer has established collaboration agreements with other leading pharmaceutical companies, including Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, to advance its research and development efforts. Headquartered in New York, New York, Pfizer Inc. continues to be a leader in the biopharmaceutical industry, driven by its mission to improve global health and well-being.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Pfizer (PFE) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Pfizer (PFE) - Stock Price & Dividends

PFE Stock Overview

Market Cap in USD 163,198m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2012-08-13

PFE Stock Ratings

Growth 5y -16.2
Fundamental -26.1
Dividend 7.60
Rel. Performance vs Sector -4.43
Analysts 3.64/5
Fair Price Momentum 23.85 USD
Fair Price DCF 24.70 USD

PFE Dividends

Yield 12m 6.15%
Yield on Cost 5y 4.93%
Dividends CAGR 5y 3.72%
Payout Consistency 98.6%

PFE Growth Ratios

Growth 12m -27.59%
Growth Correlation 12m -63%
Growth Correlation 3m 37%
CAGR 5y -4.34%
CAGR/Mean DD 5y -0.20
Sharpe Ratio 12m -1.34
Alpha vs SP500 12m -46.26
Beta vs SP500 5y weekly 0.63
ValueRay RSI 31.22
Volatility GJR Garch 1y 22.17%
Price / SMA 50 -1.32%
Price / SMA 200 -4.97%
Current Volume 32194.6k
Average Volume 20d 34489.6k

External Links for PFE Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of PFE stocks?
As of June 18, 2024, the stock is trading at USD 26.98 with a total of 32,194,647 shares traded.
Over the past week, the price has changed by -3.88%, over one month by -5.80%, over three months by -1.20% and over the past year by -28.89%.
What are the forecast for PFE stock price target?
According to ValueRays Forecast Model, PFE Pfizer will be worth about 25.9 in June 2025. The stock is currently trading at 26.98. This means that the stock has a potential downside of -3.89%.
Issuer Forecast Upside
Wallstreet Target Price 31.5 16.6
Analysts Target Price 38.7 43.3
ValueRay Target Price 25.9 -3.89

Discover Pfizer Inc: A Comprehensive Overview

History of Pfizer Inc.

Pfizer Inc., established in 1849 by Charles Pfizer and Charles F. Erhart, started as a fine chemicals business. The company's first product was an antiparasitic called santonin. Over the decades, Pfizer transformed into one of the world's premier biopharmaceutical companies. It played significant roles in medical advancements, including mass-producing penicillin during World War II and developing revolutionary drugs like Viagra and Lipitor.

Core Business

At its core, Pfizer is deeply devoted to discovering and producing healthcare solutions that improve life. Its primary focus is on developing medicines and vaccines for a plethora of medical fields, including immunology, oncology, cardiology, endocrinology, and neurology. The company prioritizes innovative research and is known for its robust pipeline of promising new therapies aimed at treating a wide range of diseases.

Side Businesses

Beside its main pharmaceutical products, Pfizer also engages in several side businesses. These include animal health products through its Zoetis division (spun off in 2013), over-the-counter (OTC) consumer health products, and various health-related digital services and platforms. These diversified interests help Pfizer maintain its financial stability and expand its healthcare impact beyond prescription medicines.

Current Market Status

As of 2023, Pfizer Inc. (NYSE: PFE) remains a leader in the pharmaceutical industry. The company has seen significant growth, largely due to the global demand for its COVID-19 vaccine, developed in partnership with BioNTech SE. This has not only boosted Pfizer's revenues but also its position in the market. However, like all companies in the sector, Pfizer faces challenges such as drug patent expirations, regulatory hurdles, and the ongoing need for innovative research and development. Despite these challenges, Pfizer's strong portfolio and pipeline, along with a proactive approach to global health crises, ensure it continues to play a vital role in the healthcare industry.